# Warfarin

## Cofarin 1mg

| 藥物代碼 | OCOF1 |
| :--- | :--- |
| 適應症 | Treatment & prophylaxis of thromboembolic disorders. |
| 副作用 | Alopecia, skin rashes of various kinds, hemorrhagic skin necrosis.Cardiovascular: Cholesterol embolus syndromeDermatologic: Tissue necrosisHematologic: HemorrhageImmunologic: Hypersensitivity reaction \(infrequent \)Ophthalmic: Intraocular hemorrhage \(5% to 11% \) |
| 禁忌 | Severe hepatic or renal disease, actual or potential haemorrhagic conditions, severe hypertension, endocarditis, ulceration of the GI & urinary tract, visceral carcinoma, endocarditis, neurosurgery, recent surgery on the eye, brain or spinal cord. Pregnancy. |
| 藥物保存方式 | room temp. |
| 用法用量 | Prevention/treatment of thrombosis/embolism: Oral: Initial dosing must be individualized. Start 2-5 mg once daily for 2 days or for healthy individuals, 10 mg once daily for 2 days; lower doses \(eg, 5 mg once daily\) recommended for patients with confirmed HIT once platelet recovery has occurred. In patients with acute venous thromboembolism, initiation may begin on the first or second day of low molecular weight heparin or unfractionated heparin therapy. Adjust dose according to INR results; usual maintenance dose ranges from 2-10 mg daily \(individual patients may require loading and maintenance doses outside these general guidelines\). |
| 肝功能異常 | 需 調 整 劑 量  There are no dosage adjustments provided in the manufacturer's labeling. However, the response to oral anticoagulants may be markedly enhanced in obstructive jaundice, hepatitis, and cirrhosis. INR should be closely monitored. |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | WHO:Compatible with breast-feeding. |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## COFARIN 5mg

| 藥物代碼 | OCOF5 |
| :--- | :--- |
| 適應症 | Treatment & prophylaxis of thromboembolic disorders. |
| 副作用 | Alopecia, skin rashes of various kinds, hemorrhagic skin necrosis.Cardiovascular: Cholesterol embolus syndromeDermatologic: Tissue necrosisHematologic: HemorrhageImmunologic: Hypersensitivity reaction \(infrequent \)Ophthalmic: Intraocular hemorrhage \(5% to 11% \) |
| 禁忌 | Severe hepatic or renal disease, actual or potential haemorrhagic conditions, severe hypertension, endocarditis, ulceration of the GI & urinary tract, visceral carcinoma, endocarditis, neurosurgery, recent surgery on the eye, brain or spinal cord. Pregnancy. |
| 藥物保存方式 | room temp. |
| 用法用量 | Prevention/treatment of thrombosis/embolism: Oral: Initial dosing must be individualized. Start 2-5 mg once daily for 2 days or for healthy individuals, 10 mg once daily for 2 days; lower doses \(eg, 5 mg once daily\) recommended for patients with confirmed HIT once platelet recovery has occurred. In patients with acute venous thromboembolism, initiation may begin on the first or second day of low molecular weight heparin or unfractionated heparin therapy. Adjust dose according to INR results; usual maintenance dose ranges from 2-10 mg daily \(individual patients may require loading and maintenance doses outside these general guidelines\). |
| 肝功能異常 | 需 調 整 劑 量  There are no dosage adjustments provided in the manufacturer's labeling. However, the response to oral anticoagulants may be markedly enhanced in obstructive jaundice, hepatitis, and cirrhosis. INR should be closely monitored. |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | WHO:Compatible with breast-feed |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

